Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates Design Therapeutics (Nasdaq: DSGN) reported fourth-quarter and full-year 2025 results and updates on its GeneTAC® clinical portfolio. Cash, cash equivalents and investment securities were $219.8 million as of December 31, 2025, which the company expects to fund operations into 2029. Three programs are advancing: DT-216P2 (FA) and DT-168 (FECD) with data anticipated in H2 2026, and DT-818 (DM1) with patient dosing planned in H1 2026. 2025 expenses included R&D of $59.1 million and net loss of $69.8 million.

#DSGN Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates

www.stocktitan.net/news/DSGN/design-therape...

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

loGO DesigN & concept ART, concept design, traditional & digital techniques

loGO DesigN & concept ART, concept design, traditional & digital techniques

#logoconcept #conceptdesign #conceptart #dsgn #traditionalart

Leading Indicators, Tuesday November 11, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Tue Nov 11th - #STAA #ORMP #ADSE #BCIC #CECO #DSGN #EWTX #GANX #HCAI #INNV #PUBM #NTHI #YEXT #VAN #SFL #NVRI #KOP #FIGS #DV #BAK - More: crystalequityresearch.com/leading-indi... - #smallcap

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results Design Therapeutics (NASDAQ:DSGN) reported progress in its GeneTAC® programs and Q2 2025 financial results. The company announced encouraging early pharmacokinetics data for DT-216P2 in Friedreich Ataxia (FA), showing favorable translation from non-human primates to humans via both intravenous and subcutaneous administration.Key developments include the ongoing RESTORE-FA Phase 1/2 trial of DT-216P2 outside the US, while addressing an FDA clinical hold notice. The company also initiated a Phase 2 biomarker trial for DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) patients. Design reported $216.3 million in cash and securities, with a Q2 net loss of $19.1 million. [ "Favorable pharmacokinetics data translation from non-human primates to humans for DT-216P2", "DT-216P2 showed improved exposure and PK parameters compared to previous formulation", "Strong cash position of $216.3 million to support pipeline development", "Advancement of multiple clinical programs including FA and FECD treatments" ]

#DSGN Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/DSGN/design-therape...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Wed Jun 4th - #AEHR #CDNA #DSGN #INDI #LVLU #MCHX #NAAS #PLAY #SSSS #TCRX #XBIT #YEXT #XPOF #PL #NOAH #MLNK #KYN #GSL #DHT #CHPT #ADNT #WULF - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 Design Therapeutics announced the dosing of its first Friedreich ataxia (FA) patient in the RESTORE-FA Phase 1/2 multiple-ascending dose trial of DT-216P2 in Australia. The trial aims to evaluate safety, tolerability, and pharmacokinetics of the drug administered through IV and subcutaneous routes. Initial data from the ongoing Phase 1 single-ascending dose trial in healthy volunteers showed favorable safety and improved exposure compared to the first-generation formulation, with no injection site thrombophlebitis reported. However, the company's IND application to expand the trial to U.S. sites has been placed on clinical hold by the FDA due to nonclinical deficiencies. Design expects to report data from the MAD trial, including frataxin expression levels after 12 weeks of dosing, in 2026.

#DSGN Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

www.stocktitan.net/news/DSGN/design-therape...

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results Design Therapeutics (NASDAQ: DSGN) reported progress in Q1 2025 across its GeneTAC® programs and financial results. The company's Phase 1 trial for DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) showed favorable results, with the treatment being well-tolerated and no adverse events reported. A Phase 2 biomarker trial is planned for H2 2025. The ongoing Phase 1 SAD trial of DT-216P2 for Friedreich Ataxia (FA) continues, with plans to initiate a Phase 1/2 MAD patient study in mid-2025. The company appointed Chris Storgard, M.D. as Chief Medical Officer. Financially, Design reported a net loss of $17.7 million for Q1 2025, with R&D expenses at $15.4 million and G&A expenses at $5.0 million. The company maintains a strong cash position of $229.7 million, expected to fund operations into 2029.

#DSGN Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/DSGN/design-therape...

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today

#DSGN Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

www.stocktitan.net/news/DSGN/design-therape...

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results Design Therapeutics (DSGN) has reported significant progress in its GeneTAC® programs and financial results for Q4 and full year 2024. The company has initiated a Phase 1 Single Ascending Dose trial of DT-216P2 in healthy volunteers for Friedreich Ataxia (FA), with patient dosing planned for mid-2025. Dosing is complete in the DT-168 Phase 1 healthy volunteer trial for Fuchs Endothelial Corneal Dystrophy (FECD), with data expected in H1 2025.The company has achieved its enrollment target for the FECD observational study with 250 patients. Additionally, Design expects to select a development candidate for Myotonic Dystrophy Type-1 (DM1) in 2025.Financial highlights include: R&D expenses: $12.2M for Q4 2024, $44.4M for full yearG&A expenses: $4.5M for Q4 2024, $18.0M for full yearNet loss: $13.7M for Q4 2024, $49.6M for full yearCash position: $245.5M as of December 31, 2024

#DSGN Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/DSGN/design-therape...

Just In: ( NASDAQ: #DSGN ) Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

#StockMarket #News

Just In: ( NASDAQ: #DSGN ) Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

#StockMarket #News

Breaking News: ( NASDAQ: #DSGN ) Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC(TM) Portfolio

#StockMarket #News